Loading
CD3G (T-cell surface glycoprotein CD3 gamma chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Leukaemia and 5 more.
Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.43, genetic association 0.00, clinical 0.98).
In plain words · CD3G (T-cell surface glycoprotein CD3 gamma chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Leukaemia and 5 more.
CD3G (T-cell surface glycoprotein CD3 gamma chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Leukaemia and 5 more.
Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response.
No product in this corpus aims at CD3G yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA CD3G: RNA tissue enriched (lymphoid tissue 88 nTPM); blood lineage lineage enriched (T-cells 242 nTPM); high antibody staining in 2 normal tissues; highest cancer staining thyroid cancer (1 of 3 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Multiple myeloma, Leukaemia, Lung cancer (all types), Neuroendocrine tumours); Open Targets associates it with 5 specific cancer types at or above 0.5 (plasma cell myeloma, diffuse large B-cell lymphoma, follicular lymphoma, acute lymphoblastic leukemia, small cell lung carcinoma). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas CD3G tissue; Open Targets ENSG00000160654 associations
First described 1986. Earliest sequence paper UniProt cites for the protein: Krissansen G.W. et al, EMBO J, 1986, "Primary structure of the T3 gamma subunit of the T3/T cell antigen receptor complex deduced from cDNA sequences: evolution of the T3 gamma and delta subunits". Source.
Sources: HGNC HGNC:1675 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P09693 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000160654 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: small cell lung carcinoma 0.56, neuroendocrine neoplasm 0.56, acute lymphoblastic leukaemia 0.57, diffuse large B-cell lymphoma 0.59, plasma cell myeloma 0.60, non-Hodgkin lymphoma 0.61 (GraphQL API, CC0))
Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signalling pathways. In addition to this role of signal transduction in T-cell activation, CD3G plays an essential role in the dynamic regulation of TCR expression at the cell surface. Indeed, constitutive TCR cycling is dependent on the di-leucine-based (diL) receptor-sorting motif present in CD3G. Location: Cell membrane (UniProt). Locus 11q23.3 (HGNC).
RNA: tissue enriched (lymphoid tissue 88 nTPM), detected in some normal tissues. Blood: lineage enriched (T-cells 242 nTPM).
Medium: Bone marrow, Lymph node.
Medium only: carcinoid, cervical cancer, colorectal cancer, endometrial cancer.
HPA CD3G tissue · HPA CD3G pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CD3G" OR ABSTRACT:"CD3G" OR TITLE:"CD3 gamma subunit of T-cell receptor complex" OR ABSTRACT:"CD3 gamma subunit of T-cell receptor complex" OR TITLE:"T-cell surface glycoprotein CD3 gamma chain" OR ABSTRACT:"T-cell surface glycoprotein CD3 gamma chain" OR TITLE:"CD3-GAMMA" OR ABSTRACT:"CD3-GAMMA" OR TITLE:"CD3GAMMA" OR ABSTRACT:"CD3GAMMA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD3G, not a curated reading list.
Shares Leukaemia (all types), Neuroendocrine tumours, Follicular lymphoma, Acute lymphoblastic leukaemia.
Shares Leukaemia (all types), Follicular lymphoma, Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Multiple myeloma, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Lung cancer (all types), Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.